These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 31508358)
1. Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel. Hopkins AM; Rowland A; McKinnon RA; Sorich MJ Front Oncol; 2019; 9():789. PubMed ID: 31508358 [No Abstract] [Full Text] [Related]
2. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine. Hopkins AM; Rowland A; Logan JM; Sorich MJ Breast; 2019 Aug; 46():90-94. PubMed ID: 31170589 [TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843 [TBL] [Abstract][Full Text] [Related]
4. Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. R Ferreira A; Ferreira S; Lambertini M; Maurer C; Martel S; Costa L; Ponde N; de Azambuja E Eur J Cancer; 2021 Feb; 144():351-359. PubMed ID: 33388492 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial. Ding N; Pang J; Liu X; He X; Zhou W; Xie H; Feng J; Wang G; Tang J; Cao J; He L; He Y; Wang S; Xiao Z Breast Cancer Res; 2024 Jan; 26(1):9. PubMed ID: 38212845 [TBL] [Abstract][Full Text] [Related]
6. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J; Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873 [TBL] [Abstract][Full Text] [Related]
8. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862 [TBL] [Abstract][Full Text] [Related]
9. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402 [TBL] [Abstract][Full Text] [Related]
10. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis . Tian T; Ye J; Zhou S Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130 [TBL] [Abstract][Full Text] [Related]
11. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663 [TBL] [Abstract][Full Text] [Related]
12. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J; N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012 [TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614 [TBL] [Abstract][Full Text] [Related]
14. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Baselga J; Swain SM Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694 [TBL] [Abstract][Full Text] [Related]
15. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247 [TBL] [Abstract][Full Text] [Related]
16. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Ligorio F; Fucà G; Zattarin E; Lobefaro R; Zambelli L; Leporati R; Rea C; Mariani G; Bianchi GV; Capri G; de Braud F; Vernieri C Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921727 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149 [TBL] [Abstract][Full Text] [Related]
18. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717 [TBL] [Abstract][Full Text] [Related]
19. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927 [TBL] [Abstract][Full Text] [Related]
20. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]